Epothilone in Recurrent Glioblastoma Patients

Summary

The purpose of this single arm phase II study is to evaluate safety and efficacy of ZK 219477 in the treatment of temozolomide pre-treated, recurrent GBM patients.

Timeline

Start

2006-06

Primary completion

2008-03

Completion

2008-12

Publications

• Background Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8. doi: 10.1002/anie.200602785. No abstract available.
• Results Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, Botturi A, Salmaggi A. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol. 2009 Oct;95(1):61-64. doi: 10.1007/s11060-009-9890-8. Epub 2009 Apr 21.

Drugs

Indications